Clearside Biomedical Goodwill and Intangible Assets 2015-2025 | CLSD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clearside Biomedical goodwill and intangible assets from 2015 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Clearside Biomedical Goodwill and Intangible Assets 2015-2025 | CLSD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clearside Biomedical goodwill and intangible assets from 2015 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$243.4B
Amgen (AMGN)	$156.3B
Gilead Sciences (GILD)	$147.7B
Vertex Pharmaceuticals (VRTX)	$100.1B
Bristol Myers Squibb (BMY)	$97.3B
CSL (CSLLY)	$85B
GSK (GSK)	$80B
Regeneron Pharmaceuticals (REGN)	$60B
Alnylam Pharmaceuticals (ALNY)	$58B
Argenex SE (ARGX)	$39.9B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$20.5B
Biogen (BIIB)	$19.8B
Incyte (INCY)	$16.8B
Illumina (ILMN)	$15.4B
Genmab (GMAB)	$14.7B
Genmab (GNMSF)	$14.3B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.4B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B
Halozyme Therapeutics (HALO)	$7.7B